168166-54-9Relevant academic research and scientific papers
Indole derivatives thromboxane A2 antagonists
-
, (2008/06/13)
Compounds of formula (I): STR1 and pharmaceutically acceptable salt and biolabile esters thereof, wherein R1 is H, C1 -C4 alkyl, phenyl optionally substituted by up to three substituents independently selected from C1 -C4 alkyl, C1 -C4 alkoxy, halogen and CF3, or is 1-imidazolyl, 3-pyridyl or 4-pyridyl; R2 is H or C1 -C4 alkyl, R3 is SO2 R4 or COR4 where R4 is C1 -C6 alkyl, C1 -C3 perfluoroalkyl(CH2)p, C3 -C6 cycloalkyl(CH2)p, aryl(CH2)p, or heteroaryl(CH2)p, p being 0, 1 or 2, or R4 may be NR5 R6 where R5 is H or C1 -C4 alkyl and R6 is C1 -C6, alkyl, C3 -C6 cycloalkyl or aryl, or R5 and R6 together with the nitrogen atom to which they are attached form a 5- to 7-membered heterocyclic ring which may optionally incorporate a carbon-carbon double bond or a further heteroatom linkage selected from O, S, NH, N(C1 -C4 alkyl) and N(C1 -C5 alkanoyl); X is CH2 or a direct link, with the proviso that when R1 is 1-imidazolyl then X is CH2 ; m is 2, or 3; n is 0, 1 or 2, and wherein the group (CH2)n NHR3 is attached at the 5-position when n is 0 or 1, or at the 5- or 4-position when n is 2. These compounds are selective TXA2 and PGH2 antagonists. Some also inhibit thromboxane synthetase.
Thromboxane modulating agents. 2. Thromboxane receptor antagonists derived from the thromboxane synthase inhibitor dazmegrel
Dickinson, Roger P.,Dack, Kevin N.,Steele, John,Tute, Michael S.
, p. 1691 - 1696 (2007/10/03)
The design of dual thromboxane synthase inhibitor/thromboxane receptor antagonists (e.g. 15) based on the structure of the thromboxane synthase inhibitor dazmegrel is described. More potent receptor antagonists (e.g. 16c) result from replacement of the pyridinyl substituent with 4-fluorophenyl. Modelling suggests the existence of more than one site capable of interacting with the aryl sulfonamide of TxA2 receptor antagonists.
